AN2 TherapeuticsAN2 Therapeutics
AT

AN2 Therapeutics

Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.

2018Active
Advertise here
About
AN2 Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, melioidosis, and NTM lung disease caused by M. abscessus, along with programs focused on targets in oncology and infectious diseases. They are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.

Technology stack

detected 2026-05-24
Est. monthly stack spend~$180/mo
Emailunknown
Hosting
AWS
Stack
jQuery
Analytics
Google Analytics 4
Capital network
Open in Market Map editor
Frequently asked

What does AN2 Therapeutics do?

AN2 Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, melioidosis, and NTM lung disease caused by M. abscessus, along with programs focused on targets in oncology and infectious diseases. They are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health…

How much funding has AN2 Therapeutics raised?

AN2 Therapeutics has raised a total of $132M in funding. The most recent round on record is Private Placement.

Where is AN2 Therapeutics headquartered?

AN2 Therapeutics is headquartered in Menlo Park, United States.

When was AN2 Therapeutics founded?

AN2 Therapeutics was founded in 2018.

What industry does AN2 Therapeutics operate in?

AN2 Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare, Drug Discovery, Life Sciences, Infectious Diseases.